
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Psoriasis epidemiology and demographics
Introduction
Overview
Overview
The prevalence of psoriasis is estimated to be between 500 and 4,600 cases annually per 100,000 people.Β Psoriasis usually affects individuals of the Caucasian race. Psoriasis tends to primarily affect Northern European and Southeast Asian countries.
Epidemiology and Demographics
Epidemiology and Demographics
Prevalence
- Worldwide, the prevalence of psoriasis ranges from a low of 500 cases per 100,000 persons to a high of 4,600 cases per 100,000 persons.[1]
- The prevalence of psoriasis in the United States is 2,000 cases per 100,000 persons.[2]
- Worldwide, the prevalence of psoriatic arthritis (PsA) ranges from a low of 100 cases per 100,000 persons to a high of 1,000 cases per 100,000 persons.[2]
- Worldwide, 7,000 per 100,000 people with arthritis are affected by psoriasis.[2]
Incidence
- Worldwide, the incidence of psoriasis ranges from a low of 78.9 cases per 100,000 persons (United States) to 230 cases per 100,000 persons (Italy).[3]
Age
- Psoriasis has two peaks with regard to age. The mean age of the first peak is between 15 years to 25 years and the mean age of the second peak is between 55 and 60 years._Annals_of_the_Rheumatic_Diseases-4|[4]
Race
- Psoriasis tends to affect Caucasians more than other races, with a prevalence of 2,500 per 100,000 Caucasian persons in the United States, which is higher than other ethnic populations in the country.[5]
Gender
- There is no gender predilection for psoriasis, although women are more severely affected than men once they have developed the disease.[6]
Geographical distribution
- Psoriasis tends to primarily affect Northern European and Southeast Asian countries.[7]
References
References
- β Langley RG, Krueger GG, Griffiths CE (2005). “Psoriasis: epidemiology, clinical features, and quality of life”. Ann. Rheum. Dis. 64 Suppl 2: ii18β23, discussion ii24β5. doi:10.1136/ard.2004.033217. PMCΒ 1766861. PMIDΒ 15708928.
- β 2.0 2.1 2.2 Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005). “Psoriatic arthritis: epidemiology, clinical features, course, and outcome”. Ann. Rheum. Dis. 64 Suppl 2: ii14β7. doi:10.1136/ard.2004.032482. PMCΒ 1766874. PMIDΒ 15708927.
- β Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013). “Global epidemiology of psoriasis: a systematic review of incidence and prevalence”. J. Invest. Dermatol. 133 (2): 377β85. doi:10.1038/jid.2012.339. PMIDΒ 23014338.
- _Annals_of_the_Rheumatic_Diseases_4-0|β “Psoriasis: epidemiology, clinical features, and quality of life | Annals of the Rheumatic Diseases”.
- β Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004). “Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction”. J. Investig. Dermatol. Symp. Proc. 9 (2): 136β9. doi:10.1046/j.1087-0024.2003.09102.x. PMIDΒ 15083780.
- β “Psoriasis – ScienceDirect”.
- β Danielsen K, Olsen AO, Wilsgaard T, Furberg AS (2013). “Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort”. Br. J. Dermatol. 168 (6): 1303β10. doi:10.1111/bjd.12230. PMIDΒ 23374051.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]
